5-(tryptophyl)amino-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based potent and selective CCK1 receptor antagonists:: Structure-activity relationship studies on the substituent at N2-position

被引:12
作者
Bartolomé-Nebreda, JM
Patiño-Molina, R
Martín-Martínez, M
Gómez-Monterrey, I
García-López, MT
González-Muñiz, R
Cenarruzabeitia, E
Latorre, M
Del Río, J
Herranz, R
机构
[1] CSIC, Inst Quim Med, E-28006 Madrid, Spain
[2] Univ Navarra, Dept Farmacol, E-31080 Pamplona, Spain
关键词
D O I
10.1021/jm010813d
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
To establish structure-activity relationships a new series of analogues of the highly potent and selective CCK1 receptor antagonist (4aS,5R)-2-benzyl-5-(N-Boc-tryptophyl)amino-1,3-dioxoperhydropyrido[1,2-c]-pyrimidine (1a) modified at N2-position of the central scaffold has been prepared and evaluated as CCK receptor ligands. With this aim the N2-benzyl group has been replaced by methyl, cyclohexyl, aromatic groups, 1-phenylethyl, and 1-carboxy-2-phenylethyl group. Then, substituents with different electronic and steric properties were introduced into different positions of the phenyl group of analogues 19a and 19b. The results of the CCK receptor binding and in vitro functional activity evaluation suggest the importance of the lipophilic character and an appropriate spatial orientation of the moiety linked at the N2-position of the 1,3-dioxoperhydropyrido[1,2-c]pyrimidine template for potent and selective binding and antagonist activity at CCK1 receptor subtype. The 2-cyclohexyl and (2S)-1-naphthyl derivatives 18a and (2S)-20a have emerged as more potent and selective CCK1 receptor antagonists than the lead compound 1a. Additionally, the results confirm the (4aS,5R)stereochemistry at the central bicyclic skeleton as an essential structural requirement for potent binding to this receptor subtype.
引用
收藏
页码:2219 / 2228
页数:10
相关论文
共 26 条
  • [1] [Anonymous], CHEM AMINO GROUP
  • [2] Pharmacological evaluation of IQM-95,333, a highly selective CCKA receptor antagonist with anxiolytic-like activity in animal models
    Ballaz, S
    Barber, A
    Fortuno, A
    DelRio, J
    MartinMartinez, M
    GomezMonterrey, I
    Herranz, R
    GonzalezMuniz, R
    GarciaLopez, MT
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1997, 121 (04) : 759 - 767
  • [3] 5-(Tryptophyl)amino-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based potent and selective CCK1 receptor antagonists:: Structural modifications at the tryptophan domain
    Bartolomé-Nebreda, JM
    Gómez-Monterrey, I
    García-López, MT
    González-Muñiz, R
    Martín-Martínez, M
    Ballaz, S
    Cenarruzabeitia, E
    LaTorre, M
    Del Río, J
    Herranz, R
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (22) : 4659 - 4668
  • [4] BARTOLOMENEBRED.JM, 1999, THESIS U AUTONOMA MA
  • [5] Chambers M S, 2000, Prog Med Chem, V37, P45, DOI 10.1016/S0079-6468(08)70057-2
  • [6] BIOLOGICAL ACTIONS OF CHOLECYSTOKININ
    CRAWLEY, JN
    CORWIN, RL
    [J]. PEPTIDES, 1994, 15 (04) : 731 - 755
  • [7] CCK in anxiety and cognitive processes
    Daugé, V
    Léna, I
    [J]. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 1998, 22 (06) : 815 - 825
  • [8] INVESTIGATION OF BEHAVIORAL AND ELECTROPHYSIOLOGICAL RESPONSES INDUCED BY SELECTIVE STIMULATION OF CCKB RECEPTORS BY USING A NEW HIGHLY POTENT CCK ANALOG, BC-264
    DAUGE, V
    BOHME, GA
    CRAWLEY, JN
    DURIEUX, C
    STUTZMANN, JM
    FEGER, J
    BLANCHARD, JC
    ROQUES, BP
    [J]. SYNAPSE, 1990, 6 (01) : 73 - 80
  • [9] de Tullio P, 1999, CURR MED CHEM, V6, P433
  • [10] CCK receptor antagonists
    Dunlop, J
    [J]. GENERAL PHARMACOLOGY, 1998, 31 (04): : 519 - 524